KU-60019: Selective ATM Kinase Inhibitor for Glioma Radiosensitization

Executive Summary: KU-60019 is a highly selective inhibitor of the ATM kinase with an IC₅₀ of 6.3 nM, displaying 270-fold and 1600-fold selectivity over DNA-PK and ATR, respectively (APExBIO). ATM kinase inhibition radiosensitizes both p53 wild-type and mutant glioma cells by reducing prosurvival AKT and ERK phosphorylation (Huang et al., 2023). KU-60019 impairs glioma cell migration and invasion dose-dependently and enhances tumor suppression when combined with radiotherapy in vivo. It is soluble at ≥27.4 mg/mL in DMSO and ≥51.2 mg/mL in ethanol, but insoluble in water. KU-60019 reveals metabolic vulnerabilities by altering nutrient uptake and macropinocytosis, expanding its use beyond radiosensitization (Huang et al., 2023).

Biological Rationale

The Ataxia Telangiectasia Mutated (ATM) kinase orchestrates DNA double-strand break repair and modulates cellular metabolism (Huang et al., 2023). ATM activation leads to cell cycle arrest, DNA repair pathway choice, and survival signaling via AKT and ERK phosphorylation. In glioma, ATM signaling promotes resistance to genotoxic stress, including ionizing radiation. Selective ATM inhibition with small molecules such as KU-60019 enables radiosensitization and exposes metabolic liabilities in tumor cells (PrecisionFDA article). This approach is especially valuable for glioblastoma models, where standard therapies often fail due to robust DNA repair and adaptive metabolism (KU-55933.com, A8336 article).

Mechanism of Action of KU-60019

Target and Inhibition: KU-60019 (A8336, APExBIO) is a potent, ATP-competitive inhibitor of ATM kinase, with an IC₅₀ of 6.3 nM under in vitro kinase assay conditions at 25°C and physiological pH (APExBIO). It exhibits 270-fold selectivity over DNA-dependent protein kinase (DNA-PK) and 1600-fold over ATR, minimizing off-target effects in DNA repair pathways.

Downstream Effects: By inhibiting ATM, KU-60019 blocks phosphorylation of downstream effectors (e.g., p53 Ser15, Chk2 Thr68), suppresses AKT and ERK activation, and disrupts prosurvival signaling (Huang et al., 2023). This impairs DNA damage response, cell survival, and repair capacity after irradiation.

Metabolic Adaptation: ATM inhibition increases macropinocytosis, enhancing branched-chain amino acid (BCAA) uptake for tumor cell survival under nutrient-poor conditions. However, combined ATM and macropinocytosis inhibition leads to cell death, revealing a metabolic vulnerability (Huang et al., 2023).

Evidence & Benchmarks

• KU-60019 inhibits ATM kinase with an IC₅₀ of 6.3 nM in biochemical assays, outperforming its predecessor KU-55933 (APExBIO).
• Shows 270-fold selectivity over DNA-PK and 1600-fold over ATR, avoiding broad DNA repair inhibition (APExBIO).
• Radiosensitizes both p53 wild-type (U87) and mutant (U1242) human glioma cell lines by reducing AKT and ERK phosphorylation and impairing DNA repair (Huang et al., 2023).
• Suppresses glioma cell migration and invasion dose-dependently, as measured by transwell and wound-healing assays (PrecisionFDA article).
• Intratumoral delivery at 10 μM for 14 days via osmotic pump in animal models significantly suppresses tumor growth when combined with radiation (Huang et al., 2023).
• ATM inhibition induces metabolic reprogramming, including increased macropinocytosis and BCAA uptake, creating a distinct vulnerability (Huang et al., 2023).

For a deeper mechanistic exploration, see this advanced ATM kinase inhibition article, which expands on metabolic adaptation beyond radiosensitization.

Applications, Limits & Misconceptions

Primary Applications:

• Radiosensitization in glioma and other solid tumor models for preclinical research (PrecisionFDA article).
• Selective inhibition of ATM kinase for dissecting DNA damage response pathways.
• Identification of metabolic vulnerabilities via altered macropinocytosis and amino acid uptake (Huang et al., 2023).
• Suppression of glioma cell migration and invasion in vitro.

Limitations:

• Not suitable for diagnostic or therapeutic use in humans (APExBIO).
• Insoluble in water; requires DMSO or ethanol for stock preparation.
• Effects in tumors with high c-MYC or mutant p53 remain incompletely characterized (Huang et al., 2023).

Common Pitfalls or Misconceptions

• KU-60019 is not a pan-PI3K or ATR inhibitor; off-target effects are minimal but should not be assumed absent.
• Results from glioma models do not automatically extrapolate to all cancer types or primary cells.
• Stock solutions degrade at >-20°C or after repeated freeze-thaw cycles; fresh preparation is recommended for critical assays.
• Product is for research use only and should not be used in humans or for diagnostic purposes.
• ATM inhibition may trigger compensatory metabolic pathways; combined targeting is necessary for synthetic lethality (Huang et al., 2023).

Workflow Integration & Parameters

Stock Preparation & Storage: Dissolve KU-60019 at ≥27.4 mg/mL in DMSO or ≥51.2 mg/mL in ethanol. Store stock solutions at -20°C. Use working solutions promptly to avoid degradation (APExBIO).

Experimental Conditions: In vitro, treat cells at 3 μM for 1–5 days depending on assay duration. In vivo, intratumoral osmotic pump delivery at 10 μM for 14 days is supported by literature benchmarks (Huang et al., 2023).

For scenario-driven protocol optimization and troubleshooting, see this guide to KU-60019 workflows, which provides actionable insights for robust, reproducible results.

Conclusion & Outlook

KU-60019 (A8336, APExBIO) is a validated, highly selective ATM kinase inhibitor that enables precision radiosensitization and reveals metabolic vulnerabilities in glioma models. Its mechanistic specificity and robust benchmarks make it a preferred tool for dissecting DNA damage response and metabolic adaptation in preclinical cancer research. Ongoing research is expanding its utility to new tumor subtypes and combination strategies, including dual inhibition of metabolic pathways (Huang et al., 2023). For further reading on integration with metabolic research, see this review of KU-60019 in metabolic vulnerability studies, which complements the present dossier by detailing advanced metabolic applications.